FDA approval for drug to treat attention deficit hyperactivity disorder

NewsGuard 100/100 Score
McNeil Consumer & Specialty Pharmaceuticals has received an approvable letter from the U.S. Food and Drug Administration (FDA) for the use of CONCERTA® (methylphenidate HCl) CII Extended-release Tablets in adolescents with Attention Deficit/Hyperactivity Disorder (ADHD) and to expand labeling to include a 72 mg dosing regimen.

FDA approval is contingent upon agreement of final labeling and submission of additional analyses from existing studies.

"We are delighted to reach this important milestone for CONCERTA® and are working closely with FDA to bring this new dosage option to patients, families and health care professionals as quickly as possible," said Minnie V. Baylor-Henry, R.Ph., J.D., vice president, Medical & Regulatory Affairs, McNeil Consumer & Specialty Pharmaceuticals.

CONCERTA® tablets are currently available in 18 mg, 27 mg, 36 mg and 54 mg strengths. "There will be no 72 mg tablet," explained Baylor-Henry. "While physicians will determine how the medication should best be taken by patients for whom it is prescribed, we believe CONCERTA® 72 mg will most often be taken as a once-a-day morning dose of two CONCERTA® 36 mg tablets."


CONCERTA® (methylphenidate HCl) CII is a once-daily extended-release formulation of methylphenidate approved to treat ADHD. The efficacy of CONCERTA® has been demonstrated in studies conducted in children and adolescents. Only a doctor can determine if medication is the right treatment for individuals with ADHD.

CONCERTA® uses an advanced OROS® extended-release delivery system to deliver a controlled rate of medication throughout the day. Because of its unique OROS® system, CONCERTA® minimizes the ups and downs in blood levels experienced with stimulant medications taken several times a day.

CONCERTA® should not be taken by patients with: significant anxiety, tension, or agitation; allergies to methylphenidate or other ingredients in CONCERTA®; glaucoma, Tourette's syndrome, tics, or family history of Tourette's syndrome; current/recent use of monoamine oxidase (MAOIs). Abuse of methylphenidate may lead to dependence. CONCERTA® should not be taken by children under six years of age.

In clinical studies with patients using CONCERTA®, the most common side effects were headache, stomach pain, sleeplessness and decreased appetite. For more information about CONCERTA®, including full U.S. prescribing information, please visit www.concerta.net or call 1-888-440-7903.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pain reliever use in pregnancy shows no link to child neurodevelopmental disorders, study finds